Cambrian BioPharma sells Sensei Biotherapeutics shares

Cambrian BioPharma Inc, a ten percent owner of Sensei Biotherapeutics, Inc., reported open-market sales of a total of 25,000 shares of Sensei common stock.

Rhea-AI Filing Summary

Cambrian BioPharma Inc, a ten percent owner of Sensei Biotherapeutics, Inc., reported open-market sales of a total of 25,000 shares of Sensei common stock. The trades on June 1, 2026 were executed at prices ranging from $20.00 to $21.00 per share, based on a weighted average price disclosure.

Insider Trade Summary

Net Seller: 25,000 shares

Net Sell 2 txns

Insider Cambrian BioPharma Inc

Role 10% Owner

Sold 25,000 shs ($501K)

Type	Security	Shares	Price	Value
Sale	Common Stock	24,524	$20.00	$490K
Sale	Common Stock	476	$21.14	$10K

Holdings After Transaction: Common Stock — 130,142 shares (Direct)

Footnotes (1)

1. F1. The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

Key Figures

Shares sold (first trade): 476 shares Price per share (first trade): $21.14 per share Shares sold (second trade): 24,524 shares +2 more

5 metrics

Shares sold (first trade) 476 shares Common Stock sold at $21.14 per share on June 1, 2026

Price per share (first trade) $21.14 per share Open-market sale of 476 Common Stock shares on June 1, 2026

Shares sold (second trade) 24,524 shares Common Stock sold at $20.00 per share on June 1, 2026

Price per share (second trade) $20.00 per share Open-market sale of 24,524 Common Stock shares on June 1, 2026

Total shares sold 25,000 shares Aggregate of reported open-market sales in Form 4 transaction summary

Key Terms

open-market sale, weighted average price, ten percent owner

3 terms

open-market sale financial

"transaction_action is described as an open-market sale of Common Stock"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

ten percent owner financial

"Cambrian BioPharma Inc is indicated as a ten percent owner of the issuer."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did Cambrian BioPharma report for Sensei Biotherapeutics (SNSE)?

Cambrian BioPharma Inc reported selling a total of 25,000 shares of Sensei Biotherapeutics common stock. The transactions were open-market sales executed on June 1, 2026, according to the Form 4 insider trading report.

At what prices were the SNSE shares sold by Cambrian BioPharma?

The filing reports a weighted average price for the trades, with shares sold in a price range from $20.00 to $21.00 per share. One line item shows 24,524 shares sold at $20.00 per share.

How many SNSE shares did Cambrian BioPharma sell in each transaction?

Cambrian BioPharma reported two open-market sales of Sensei Biotherapeutics common stock. One sale covered 476 shares at $21.14 per share, and the other covered 24,524 shares at $20.00 per share, totaling 25,000 shares sold.

What does the Form 4 say about Cambrian BioPharma’s ownership status in SNSE?

Cambrian BioPharma Inc is identified as a ten percent owner of Sensei Biotherapeutics. The reported transactions involve direct ownership of common stock, as indicated by the direct ownership code in the filing’s non-derivative transaction table.

How does the Form 4 describe the pricing details for Cambrian BioPharma’s SNSE sales?

The Form 4 notes that the Column 4 price is a weighted average price. It explains that the shares were sold between $20.00 and $21.00, and offers to provide detailed per-trade pricing information to the issuer, shareholders, or SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/01/2026 - 05:21 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cambrian BioPharma Inc

(Last) (First) (Middle)

228 PARK AVENUE S.

#66643

(Street)

NEW YORK NEW YORK 10003

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Sensei Biotherapeutics, Inc. [ SNSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/01/2026		S		24,524	D	$20(1)	130,618	D
Common Stock	06/01/2026		S		476	D	$21.14	130,142	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The prices sold ranged from $20.00 to $21.00. The reporting person will provide the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range.

	Cambrian BioPharma Inc, by: /s/ James Peyer	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)